data showing hemodynamic deterioration in patients with Atrial Septal Defect (ASD) than in Ventricular Septal Defect\r\n(VSD).\r\nMethod: A proof of concept study was designed to evaluate effect of bosentan treatment for 12 months using both\r\nclinical outcome and Cardiac Magnetic Resonance (CMR).\r\nResults: Ten patients were enrolled with average age of 39.7 �± 9.7 years. There were 5 ASD and 5 VSD in each\r\ngroup. There is no statistical significance in baseline data among both groups. During the follow up period there is an\r\nimprovement of 6 Minute Walk Distance (6 MWD) at 4 months, but the effect levels off at 12 months. Patients with VSD\r\ngroup showed better improvement of 6 MWD more than in ASD group (p=0.52 at 4 months and p=0.009 at 12 months).\r\nAll CMR findings were not statistically different at 12 months. However, patients who had VSD showed significant\r\nimprovement in RV EF from baseline of 54.6 �± 14.5% to 56.27 �± 13.79% and 57.53 �± 7.66% when compared to ASD\r\nof 38.3 �± 11.5% to 38.72 �± 10.55% and 39.24 �± 10.80% at 4 months and 12 months respectively (p=0.025).\r\nConclusion: We demonstrated improvement of 6 MWD in ES with bosentan treatment for 12 months. We were\r\nnot able to show improvement in CMR parameter at 12 months, however, when compared, VSD group had significant\r\nimprovement in RVEF to ASD group.
Loading....